http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Youngah Yoo (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
-
Yoo, Young Sook,Jo, Youngah,Park, Jung-Gyu,Kim, Yun Taik The Korea Science and Technology Center 1998 BMB Reports Vol.31 No.5
Membrane depolarization in PC12 cells induces calcium influx via an L-type voltage-sensitive calcium channel (L-VSCC) and increases intracellular free calcium, which leads to tyrosine phosphorylation of epidermal growth factor (EGF) receptor and the associated adaptor protein, Shc. This activated EGF receptor complex then can activate mitogen-activated protein (MAP) kinase, as in nerve growth factor (NGF) receptor activation. In the present study, we investigated the role of EGF receptor in the signaling pathway initiated by membrane depolarization of PC12 cells. Prolonged membrane depolarization induced phosphorylation of extracellular signal-regulated kinase (ERK) within 1 min undifferentiated PC12 cells. Pretreatment of PC12 cells with the calcium chelator EGTA abolished depolarization-stimulated ERK phosphorylation, but NGF-induced phosphorylation of ERK was not affected. The chronic treatment of phorbol ester, which down-regulated the activity of protein kinase C (PKC), did not affect the phosphorylation of ERK upon depolarization. In the presence of an inhibitor of EGF receptor, neither depolarization nor calcium ionophore increased the level of ERK phosphorylation. These data imply that the EGF receptor is functionally necessary to activate ERK and neurite outgrowth in response to the prolonged depolarization in PC12 cells, and also that PKC is apparently not involved in this signaling pathway.
-
( Kyungil Kim ),( Ida Rune ),( Sanne S. Veidal ),( Keun-wan Lim ),( Yunsun Park ),( Youngah Kim ),( Leo S. Choi ),( Henrik H. Hansen ),( Michael Feigh ),( Sang-ku Yoo ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: HSG4112, a synthetic new chemical entity, is a first-inclass oral small molecule in clinical development for obesity. In preclinical studies, HSG4112 as mitochondrial function enhancer has been demonstrated to increase energy expenditure and decrease chronic low-grade inflammation, resulting in reduced adiposity and robust weight loss. As these therapeutic effects are highly relevant for the management of non-alcoholic steatohepatitis (NASH), we aimed to compare the therapeutic effects of HSG4112 and semaglutide (GLP-1 receptor agonist) in a diet-induced obese (DIO) and biopsy-confirmed mouse model of NASH. Methods: Male C57BL/6JRj mice were fed AMLN diet high in trans-fat, fructose and cholesterol for 35 weeks. Only animals with liver biopsy-confirmed steatosis (score ≥2) and fibrosis (stage ≥F1) were included and stratified into treatment groups according to baseline body weight and liver collagen-1a1 deposition. DIO-NASH mice received vehicle (PO, QD), HSG4112 (50 or 100 mg/kg, PO, QD), or semaglutide (30 nmol/kg, SC, QD) for 10 weeks. Endpoints included within-subject changes in body composition, NAFLD Activity Score (NAS) and fibrosis stage as well as terminal quantitative liver histology and transcriptome analysis. Results: HSG4112 and semaglutide induced similar reductions in body weight (20%) and whole-body fat levels (10-12%) in DIO-NASH mice. These metabolic effects were accompanied by significantly reduced plasma levels of liver injury markers (ALT, AST, ALP). Notably, in contrast to semaglutide, HSG4112 did not reduce any food intake and improved NAS by a different mode of action. Accordingly, HSG4112 specifically attenuated lobular inflammation while semaglutide reduced steatosis severity. Both compounds significantly reduced fibrogenesis activity associated with suppressed stellate cell activation and lowered collagen mRNA expression. Conclusions: HSG4112 showed robust anti-obesity and anti- NASH efficacy, especially with reduced liver inflammation and fibrogenesis, in DIO-NASH mice with biopsy-confirmed liver pathology. While its efficacy was comparable to that of semaglutide, HSG4112 did not reduce food intake, further demonstrating its energy expenditure-enhancing effect. These findings suggest HSG4112 as a potent novel drug for the treatment of NASH.
-
공공기관 기업부설연구소의 현주소 및 활성화 방안: 가스연구원을 중심으로
이승호(Seungho Lee),김영근(YoungKeun Kim),김동민(Dong-Min Kim),유정수(Jungsoo yoo),이영석(Young Suk Lee),조영아(Youngah Cho) 한국기술혁신학회 2019 한국기술혁신학회 학술대회 발표논문집 Vol.2019 No.11
In Korea, the Corporate Research Institute exists as a branch of public research institution. Such facilities, including the gas research institute, are currently struggling in financial and human resource as they are unable to secure investments comparable to that of private corporations. The inherent limit of most institutions stems from their tendency to maintain small-scale teams, thus making it all the more difficult to engage in more challenging research. In order to overcome such obstacles, Gas research institute have made various attempts to revolutionize R&D innovation. Improvement measures for the organization, human Resource management, and R&D processes have been reviewed, and efforts are being made to vitalize researchers. Open innovation is enlarged, decisions are made, and intensive strategies are implemented to promote new-growth. However, many research programs lack supporting staff resulting in decreased immersion in its studies. This results in overlapping research inside the agency. Small scale dispersion research also decreases the synergy effect among the group. The special law for national R&D innovation includes the improvement of government-funded research institutes and universities, but the laboratories of public institutions are in blind spots. As part of overcoming these limitations, the integrated operation plan of corporate R&D institutions of public gas and petroleum energy sector was reviewed.
DBpia
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
